Modular Medical Inc. has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions, scheduled to take place from June 20-23, 2025, in Chicago, Illinois. The company will present findings from a study investigating the pump delivery of a GLP-1R agonist, specifically exenatide, in comparison to intermittent dosing of semaglutide. The presentation, set for June 22, 2025, will feature a poster titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse." This study examines the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in diet-induced obese mice. Results from this study will be shared during a General Poster Session at the event.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。